Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers (FUSIONIV)
Cervical Cancer, Uterine Cancer
About this trial
This is an interventional treatment trial for Cervical Cancer focused on measuring Ontogenetic surgery, TMMR, PMMR, LEER
Eligibility Criteria
Inclusion Criteria:
- Female, Age ≥ 20 years
- Patients with primary, recurrent, or refractory cervical cancer (FIGO stage IB1-IVA), primary, recurrent, or refractory uterine cancer (FIGO stage IA, grade 3, IB-IVA), or gynecologic cancer patients showing pelvic sidewall recurrence.
- ECOG performance status 0 or 1
- Extensive surgery might be expected to cure the disease, or expected to relieve severe pelvic pain.
- Patients who signed an approved informed consent
- Patients who do not have a treatment option other than surgery.
Exclusion Criteria:
- Female, Age < 20 years
- ECOG performance status ≥2
- Bilateral pelvic sidewall invasion
- Patients who had undergone radical hysterectomy, trachelectomy, or hysterectomy in case of the primary disease.
- Patients who refused to sign an informed consent
Sites / Locations
- Seoul National University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Cervical cancer
Uterine cancer
Cervical cancer, pelvic sidewall invasion
Non-cervical cancer, pelvic sidewall invasion
Primary cervical cancer patients, FIGO stage IB1-IIB Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy
Primary uterine cancer patients, FIGO stage IA, grade3, IB-IVA Refractory uterine cancer who does not respond to concurrent chemoradiotherapy or radiotherapy Recurrent uterine cancer after concurrent chemoradiotherapy or radiotherapy
Cervical cancer patients showing pelvic sidewall invasion Primary cervical cancer Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy
Gynecologic cancer patients other than cerivcal cancer, showing pelvic sidewall invasion with or without distant metastasis Patients showing uncontrolled pelvic pain due to the tumor invasion